United Therapeutics (NASDAQ:UTHR) Hits New 12-Month High on Analyst Upgrade

United Therapeutics Corporation (NASDAQ:UTHR)’s stock price hit a new 52-week high during mid-day trading on Tuesday after TD Cowen raised their price target on the stock from $575.00 to $660.00. TD Cowen currently has a buy rating on the stock. United Therapeutics traded as high as $607.89 and last traded at $588.36, with a volume of 1721854 shares traded. The stock had previously closed at $522.83.

A number of other research analysts have also weighed in on UTHR. Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. HC Wainwright increased their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $466.00 to $486.00 and gave the stock an “equal weight” rating in a research note on Monday, March 23rd. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $557.64.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $535.90, for a total value of $5,359,000.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,115,648.40. This trade represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $529.95, for a total value of $4,398,585.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $23,938,901.40. This represents a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 333,820 shares of company stock worth $165,495,478 in the last three months. 10.30% of the stock is owned by corporate insiders.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 (Tyvaso) pivotal success — the 598‑patient Phase 3 trial met its primary endpoint, showing a Hodges‑Lehmann estimate of +130.1 mL change in absolute FVC at week 52 vs. placebo, a clinically meaningful result that expands Tyvaso’s potential market beyond PAH. Read More.
• Positive Sentiment: Ralinepag Phase 3 readout + buyback momentum — investors are still digesting positive ADVANCE OUTCOMES ralinepag data (large reduction in clinical‑worsening risk) and United Therapeutics’ board authorized up to $2B in buybacks with ~$1.5B in ASRs, which accelerates share‑count reduction and supports EPS. Read More.
• Positive Sentiment: Surge in call‑option activity — unusually large options flow (≈16,800 calls, ~789% above normal) signals bullish positioning and likely amplified intraday upside through speculative buying and short‑covering. (Market data entry)
• Positive Sentiment: Analyst lift — TD Cowen raised its price target to $660 and reiterated a Buy view, which likely reinforced investor conviction after the clinical news. Read More.
• Neutral Sentiment: Read‑through to peers — some smaller respiratory/rare‑disease names saw moves on trial read‑throughs and analyst notes (e.g., Insmed), but the competitive or regulatory implications for other firms remain speculative. Read More.
• Negative Sentiment: Insider selling — CEO Martine Rothblatt sold 9,500 shares on March 26, and public filings show extensive insider sales over recent months; while not unusual for a high‑value stock, heavy insider disposals can be perceived as a headwind by some investors. Read More.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. raised its position in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. Advisors Asset Management Inc. lifted its holdings in United Therapeutics by 3.1% in the second quarter. Advisors Asset Management Inc. now owns 4,013 shares of the biotechnology company’s stock valued at $1,153,000 after acquiring an additional 121 shares during the last quarter. Choreo LLC purchased a new position in United Therapeutics in the second quarter worth approximately $220,000. Elevation Point Wealth Partners LLC purchased a new position in United Therapeutics in the second quarter worth approximately $53,000. Finally, Grantham Mayo Van Otterloo & Co. LLC increased its stake in United Therapeutics by 256.4% during the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 8,989 shares of the biotechnology company’s stock worth $2,583,000 after acquiring an additional 6,467 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Up 12.5%

The company has a market cap of $25.79 billion, a PE ratio of 21.09, a P/E/G ratio of 1.88 and a beta of 0.84. The stock has a 50-day simple moving average of $498.42 and a 200 day simple moving average of $474.96.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.19 EPS. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.